$0.01
+0.00 (+5.31%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CERO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)NCT06834282Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Part 1)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CER-1236, Cyclophosphamide, Fludarabine, Mesna | AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 18 | 2026-12-31 | in 134 d | 2026-03-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19